Re: predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria
- PMID: 22581974
- DOI: 10.1093/jnci/djs243
Re: predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria
Comment on
-
Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria.J Natl Cancer Inst. 2012 Jan 18;104(2):159-62. doi: 10.1093/jnci/djr490. Epub 2011 Dec 2. J Natl Cancer Inst. 2012. PMID: 22138096 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous